NATHAN RABINOVITCH, MD
Medical Practice at Jackson St, Denver, CO
License number
Colorado 34402
Category
Osteopathic Medicine
Type
Allergy & Immunology
License number
Colorado 34402
Category
Medical Practice
Type
Pediatrics
Address
Address
1400 Jackson St, Denver, CO 80206
Phone
(303) 388-4461
(303) 270-2174 (Fax)
(303) 270-2174 (Fax)
Personal information
See more information about NATHAN RABINOVITCH at radaris.comName
Address
Phone
151 S Olive St, Denver, CO 80230
151 Olive St, Denver, CO 80230
151 Olive St, Denver, CO 80230
6770 Cedar Ave, Denver, CO 80224
6772 Cedar Ave, Denver, CO 80224
Professional information
See more information about NATHAN RABINOVITCH at trustoria.com
Dr. Nathan Rabinovitch, Denver CO - MD (Doctor of Medicine)
Dr. Nathan Rabinovitch, Denver CO - MD (Doctor of Medicine)
Specialties:
Pediatrics, Allergy & Immunology
Address:
1400 Jackson St, Denver 80206
(303) 388-4461 (Phone)
(303) 388-4461 (Phone)
Certifications:
Allergy & Immunology, 1997, Pediatrics, 1992
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1400 Jackson St, Denver 80206
National Jewish Health
1400 Jackson St, Denver 80206
National Jewish Health
1400 Jackson St, Denver 80206
Education:
Medical School
McGill University Faculty Of Medicine
Graduated: 1989
Albert Einstein College Of Medicine Program
National Jewish Medical and Research Center
McGill University Faculty Of Medicine
Graduated: 1989
Albert Einstein College Of Medicine Program
National Jewish Medical and Research Center
Nathan Rabinovitch, Denver CO
Nathan Rabinovitch, Denver CO
Specialties:
Allergist
Address:
1400 Jackson St, Denver, CO 80206
Board certifications:
American Board of Allergy and Immunology Certification in Allergy and Immunology
Measurement And Analysis Of Leukotrienes
Measurement And Analysis Of Leukotrienes
US Patent:
2010011, May 6, 2010
Filed:
Oct 19, 2009
Appl. No.:
12/581436
Inventors:
Michael Armstrong - Aurora CO, US
Nichole Ann-Marie Reisdorph - Centennial CO, US
Nathan Rabinovitch - Denver CO, US
Nichole Ann-Marie Reisdorph - Centennial CO, US
Nathan Rabinovitch - Denver CO, US
International Classification:
G01N 33/542, C12Q 1/02, C12Q 1/26, H01J 49/26
US Classification:
435 792, 435 29, 435 25, 250282
Abstract:
The present invention provides a new analytical method for measuring leukotrienes in a clinical sample using liquid chromatography and tandem mass spectrometry (LCMSMS). The method provides a simple, rapid and low-cost assay for the measurement of leukotriene levels in a clinical sample with high accuracy and precision over the physiological range. The present invention further provides a method to determine the susceptibility of a subject to treatment with a leukotriene modifier, as wells as methods for diagnosis of a chronic obstructive disease of the airways and for predicting the risk of exacerbation of the same.
Leukotrienes And Asthma Exacerbation Risk
Leukotrienes And Asthma Exacerbation Risk
US Patent:
2014003, Feb 6, 2014
Filed:
Jan 4, 2012
Appl. No.:
13/978182
Inventors:
Nathan Rabinovitch - Denver CO, US
Assignee:
NATIONAL JEWISH HEALTH - Denver CO
International Classification:
G01N 33/92, A61K 31/137, G01N 33/53
US Classification:
514653, 436501, 436 71
Abstract:
The invention provides methods for predicting the risk for a subject of exacerbation of an inflammatory disease of the airways upon exposure to an environmental agent as well as methods for reducing a subject's risk of exacerbation of an inflammatory disease of the airways upon exposure to an environmental agent.
Methods To Determine Suceptibility To Treatment With Leukotriene Modifiers
Methods To Determine Suceptibility To Treatment With Leukotriene Modifiers
US Patent:
2009023, Sep 17, 2009
Filed:
Mar 16, 2009
Appl. No.:
12/404984
Inventors:
Nathan Rabinovitch - Denver CO, US
Erwin Gelfand - Englewood CO, US
Erwin Gelfand - Englewood CO, US
International Classification:
A61K 31/47, A61K 31/404, A61K 31/41, A61K 31/381, G01N 33/92
US Classification:
514311, 514415, 514382, 514443, 436 71
Abstract:
The present invention provides a method of determining the susceptibility of a subject to treatment with a leukotriene modifier by determining the subject's cysteinyl leukotriene (CysLT) level and the subject's level of eosinophilic airway inflammation and identifying a subject with a high ratio of CysLT levels to eosinophilic airway inflammation as susceptible to treatment with the leukotriene modifier. Also discussed is a method of treatment of subjects who are susceptible to treatment that includes administering a leukotriene modifier to such a subject.